Description
ResMed Goes Beyond Sleep Apnea — Here’s Why Its Noctrix Health Acquisition Matters!
ResMed Inc. reported its third-quarter fiscal 2026 results with an 11% headline revenue increase, or 8% on a constant currency basis, supported by growth across its device, mask, and software portfolios. Gross margin expanded by 290 basis points year over year to 62.8%, driven by supply chain improvements, manufacturing efficiencies, and favorable product mix. The company noted ongoing efforts to optimize costs and implement long-term gross margin improvement initiatives, despite emerging inflationary pressures on components and fuel costs. Operating profit rose 18%, aided by margin expansion and revenue growth, with a non-GAAP operating margin improving to 36.7%. Earnings per share grew by 21% on a non-GAAP basis, supported partially by foreign exchange benefits. Geographically, sales in the Americas grew 9%, with masks and accessories leading at 14% growth, while device sales increased by 6%.



